Following the completion of the project in the Vinnova program Innovation for Future Health 2014, ”Validation of a new platelet-based diagnostic method for early detection of cancer” NeoProteomics is now starting next level. This is a project that includes the product development of a product specifically for colorectal cancer. The project that has been granted 1.99 MSEK in Vinnova funding is called ”Minimally invasive test for early diagnosis of colorectal cancer using biomarkers in platelets”. The project will be run for 2 years and include partners from Sweden, UK and Germany.
In close collaboration with Karolinska Hospital in Stockholm, NMI in Tübingen and BILS in Umeå, NeoProteomics validates the first biomarker panel for diagnosis of ovarian cancer. The study is based on a large number of patients from Karolinska Hospital, Stockholm. Following validation, a product development of an antibody-based analysis will be initiated.
VINNOVA grants NeoProteomics AB 4.86 MSEK in funding for the project ”Validation of Platelet-based diagnostics for early detection of cancer”. The grant is for three years and comes from the program Innovation for Future Health 2014. Partners in the project are the Karolinska Hospital, Stockholm and the Akademiska Hospital, Uppsala
The company submits the first provisional patent application, covering the new method that enables diagnosis of cancer biomarkers from platelets in blood, which has been developed in Professor Gert Auer’s laboratory at Karolinska Institutet, Stockholm